The therapeutic effects of metformin on NAFLD-related liver injury are possibly due, at least in part, to metabolic improvement through signaling pathways beyond the Ethe1/Keap1/Nrf2/PINK1/Parkin pathway. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.